, Columnist
Pfizer Channels Its Inner Biotech
Four pipeline castoffs should fetch a higher valuation standing alone.
This article is for subscribers only.
Why let biotech have all the fun?
In keeping with a trend of smaller firms raising buckets of cash using Big Pharma's cast-off drugs, Pfizer Inc. is adapting the strategy for itself by spinning off four pipeline drugs into a new company called SpringWorks Therapeutics.